Base de dados : MEDLINE
Pesquisa : D02.092.782.258.368.050 [Categoria DeCS]
Referências encontradas : 3695 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 370 ir para página                         

  1 / 3695 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386437
[Au] Autor:Nagasato A; Nakamura M; Kamimura H
[Ad] Endereço:Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University.
[Ti] Título:[Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants].
[So] Source:Yakugaku Zasshi;138(2):237-242, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: Methylxanthine is widely administered for the treatment of apnea of prematurity in many countries, and previous reports have clearly established that caffeine is effective for the treatment of apnea of prematurity. In Japan, caffeine has been available since December 2014. Thus, we compared the efficacy and safety of caffeine with that of aminophylline in our hospital. There was no significant difference between the caffeine group and aminophylline group regarding the characteristics of the study patients. The mean efficacy rate from day 1 to day 10 was 89.5% in the caffeine group, and 81.9% in the aminophylline group, although the rate of improvement in apnea episodes each day from day 1 to day 10 was not significantly different between the two groups. On the other hand, the adverse event rates in the caffeine group and the aminophylline group were 70.6% and 75.0%, respectively. No significant difference was observed in the adverse event rates between the two groups. Moreover, suspected abdominal distension due to the drug administration was more frequently observed with the aminophylline group. Our findings indicate that caffeine is as effective as aminophylline, while it is superior to aminophylline regarding its overall safety.
[Mh] Termos MeSH primário: Aminofilina/administração & dosagem
Apneia/tratamento farmacológico
Cafeína/administração & dosagem
Recém-Nascido Prematuro
[Mh] Termos MeSH secundário: Administração Oral
Aminofilina/efeitos adversos
Apneia/etiologia
Cafeína/efeitos adversos
Feminino
Seres Humanos
Recém-Nascido
Infusões Intravenosas
Masculino
Segurança
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
27Y3KJK423 (Aminophylline); 3G6A5W338E (Caffeine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00144


  2 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28474588
[Au] Autor:Shivakumar M; Jayashree P; Najih M; Lewis LES; Bhat Y R; Kamath A; Shashikala -
[Ad] Endereço:Departments of Pediatrics and *Community Medicine, Women and Child block, Kasturba Hospital, Manipal. Correspondence to: Dr Leslie Edward Simon Lewis, Professor and Unit Head, Neonatal Intensive Care Unit, Department of Pediatrics, Kasturba Hospital, Manipal University Manipal 576 104, India. leslielewis1@gmail.com.
[Ti] Título:Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
[So] Source:Indian Pediatr;54(4):279-283, 2017 Apr 15.
[Is] ISSN:0974-7559
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity. STUDY DESIGN: Randomized controlled trial. SETTING: Tertiary-care referral centre and a teaching institution in Southern India. Trial was conducted from February 2012 to January 2015. PARTICIPANTS: 240 preterm (≤34 wk) neonates with apnea of prematurity. INTERVENTIONS: Neonates randomized into two groups: Caffeine group received loading dose of caffeine citrate (20 mg/kg) followed by 5 mg/kg/day maintenance dose every 24 hour. Aminophylline group received loading dose of Aminophylline - 5 mg/kg and maintenance dose of 1.5 mg/kg 8-hourly. OUTCOME MEASURES: Difference in apneic spells, associated respiratory morbidity, and acute adverse events were assessed. Association of efficacy with therapeutic drug levels was also evaluated. RESULTS: Infants on aminophylline experienced less apnea spells in 4-7 days of therapy (P=0.03). Mean apnea rate and isolated desaturations were similar in 1-3, 4-7 and 8-14 days of therapy. No difference was noted in duration of Neonatal Intensive Care Unit stay and hospital stay. Mean heart rate was significantly high in Aminophylline group (P<0.001). Risk of developing tachycardia was less (RR 0.30; 95% CI range 0.15 to 0.60; P<0.001) in Caffeine- over Aminophylline-treated infants. CONCLUSION: Aminophylline is as effective as caffeine for prevention of apneic spells in preterm neonates; however, dosage optimization needs to be done to reduce toxicity.
[Mh] Termos MeSH primário: Aminofilina/uso terapêutico
Apneia/tratamento farmacológico
Cafeína/uso terapêutico
Doenças do Prematuro/tratamento farmacológico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Recém-Nascido
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
27Y3KJK423 (Aminophylline); 3G6A5W338E (Caffeine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170506
[St] Status:MEDLINE


  3 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28355126
[Au] Autor:Wang X; Li C; Du C; Gao JL; Zhao KX; Shi R; Jiang Y
[Ad] Endereço:Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei Province 050017, China.
[Ti] Título:Plasma protein binding monitoring of therapeutic drugs in patients using single set of hollow fiber centrifugal ultrafiltration.
[So] Source:Bioanalysis;9(7):579-592, 2017 Apr.
[Is] ISSN:1757-6199
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: Plasma protein binding (PPB), as a significant influenced factor of pharmacokinetic and pharmacodynamic properties of a medicine, is a suitable index for therapeutic drug monitoring (TDM) strategies. A suitable measurement technique of PPB of patients is in urgent need and attracts many analysts' attention. Results & methodology: In this study, a novel method was proposed to analyze free drug concentration and total drug concentration (C ) successively in one unit with a sample. All RSDs were less than 3%. The absolute recovery of C ranged from 98.1 to 101.2%. DISCUSSION & CONCLUSION: It is extremely valuable to consider PPB as an important index for TDM, perfecting information of medication, reflecting the disease condition more comprehensively, providing assistance for doctors to adjust the dose regimen. The proposed technique, convenience, accuracy and without the influence of plasma condition, provides a feasible method to monitor PPB of various patients, facilitating the popularization of monitoring PPB in TDM.
[Mh] Termos MeSH primário: Aminofilina/metabolismo
Proteínas Sanguíneas/metabolismo
Centrifugação/métodos
Monitoramento de Medicamentos/métodos
Plasma/metabolismo
Doenças Respiratórias/tratamento farmacológico
Ultrafiltração/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Broncodilatadores/metabolismo
Feminino
Seres Humanos
Masculino
Meia-Idade
Ligação Proteica
Doenças Respiratórias/metabolismo
Ultrafiltração/instrumentação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Proteins); 0 (Bronchodilator Agents); 27Y3KJK423 (Aminophylline)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170508
[Lr] Data última revisão:
170508
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE
[do] DOI:10.4155/bio-2016-0257


  4 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28328807
[Au] Autor:Cui AH; Zhao J; Liu SX; Hao YS
[Ad] Endereço:Department of Pediatrics, Liaocheng People's Hospital, Liaocheng, Shandong Province, PR China.
[Ti] Título:Associations of IL-4, IL-6, and IL-12 levels in peripheral blood with lung function, cellular immune function, and quality of life in children with moderate-to-severe asthma.
[So] Source:Medicine (Baltimore);96(12):e6265, 2017 Mar.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pediatric asthma has gained increasing concerns with poorly understood pathogenesis. The purpose of this study was to explore the associations of interleukin-4 (IL-4), IL-6, and IL-12 levels in peripheral blood (PB) with lung function, cellular immune function, and children's quality of life (QOL) with moderate-to-severe asthma. METHODS: A total of 1158 children with moderate-to-severe asthma (the experimental group) and 1075 healthy children (the control group) were recruited for our study. Enzyme-linked immunosorbent assay was used to detect IL-4, IL-6, and IL-12 levels. T lymphocytes were detected by alkaline phosphatase antialkaline phosphatase, and erythrocyte immune was measured by red blood cell C 3b receptor (RBC-C3bR) rosette-forming test. The forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF) were detected, after which FEV1/forced vital capacity (FVC) was calculated before and after treatment. PedsQL3.0 was used to measure the effect of asthma on QOL of children, and the correlation between IL-4, IL-6, and IL-12 levels and the lung function and QOL was measured. Logistic regression analysis was applied to detect related factors of moderate-to-severe asthma of children. RESULTS: After treatment, the decreased IL-4 and IL-6 levels and increased IL-12 level were revealed in the experimental group. The cellular immune function's disorder was significantly decreased, and an elevated CD3, CD4, CD8, and declined CD4/CD8 level was performed in T lymphocytes. RBC-C3bR was increased, and red blood cell immune complex (RBC-IC) was reduced in erythrocyte immune in comparison with those before treatment. Lung function parameters all increased. After treatment, the symptoms of asthma in children reduced with scores of increased QOL. IL-4 was positively related to RBC-IC, but negatively associated with the QOL score. IL-6 showed negative connection with CD4/CD8, RBC-C3bR, FEV1/FVC, and QOL score, and had positive connection with PEF. In addition, IL-12 was negatively correlated with PEF. The levels of IL-4, RBC-C3bR, FEV1/FVC, and PEF were independent risk factors for the prognosis of treatment for children with moderate-to-severe asthma. CONCLUSION: This study demonstrated that IL-4, IL-6, and IL-12 levels in PB were associated with lung function, cellular immune function, and QOL in children with moderate-to-severe asthma.
[Mh] Termos MeSH primário: Aminofilina/uso terapêutico
Asma/tratamento farmacológico
Asma/imunologia
Broncodilatadores/uso terapêutico
Interleucinas/sangue
Qualidade de Vida
[Mh] Termos MeSH secundário: Complexo Antígeno-Anticorpo/metabolismo
Criança
Pré-Escolar
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Interleucina-12/sangue
Interleucina-4/sangue
Interleucina-6/sangue
Pulmão/patologia
Masculino
Receptores de Complemento 3b/metabolismo
Testes de Função Respiratória
Índice de Gravidade de Doença
Linfócitos T/metabolismo
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigen-Antibody Complex); 0 (Bronchodilator Agents); 0 (Interleukin-6); 0 (Interleukins); 0 (Receptors, Complement 3b); 187348-17-0 (Interleukin-12); 207137-56-2 (Interleukin-4); 27Y3KJK423 (Aminophylline)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006265


  5 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219599
[Au] Autor:Seo K; Choi JW; Kim DW; Han D; Noh SJ; Jung HS
[Ad] Endereço:Department of Anesthesiology and Pain Medicine, St Vincent's Hospital, The Catholic University of Korea, Seoul, Korea.
[Ti] Título:Aminophylline Effect on Renal Ischemia-Reperfusion Injury in Mice.
[So] Source:Transplant Proc;49(2):358-365, 2017 Mar.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Aminophylline increases the intracellular concentration of cAMP and exerts an anti-inflammatory effect. The aim of this study was to investigate the effect of aminophylline on renal ischemia-reperfusion (I/R) injury in mice. METHODS: Thirty C57BL/6 mice were divided into 3 groups. In the sham group (group S, n = 10), only right nephrectomy was performed. In the control group (group C, n = 10), after right nephrectomy, the mice were subjected to 30 minutes of left renal ischemia. In the aminophylline group (group A, n = 10), an intraperitoneal injection of aminophylline (5 mg/kg) was performed before renal ischemia. Twenty-four hours after reperfusion, the mice were euthanized, and plasma and kidney samples were obtained to analyze the serum creatinine, renal histology, and expression levels of nuclear factor-kappa B (NF-kB) and pro-inflammatory cytokines. RESULTS: The serum creatinine concentration in group C was markedly elevated at 24 hours after reperfusion. Aminophylline treatment significantly reduced serum creatinine, compared with group C. Aminophylline also reduced the histological evidence of renal damage. The expression levels of NF-kB, tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-2 (MIP-2), and intercellular adhesion molecule-1 (ICAM-1) mRNA were significantly increased in group C (P < .001). Group A showed lower expression of NF-kB, TNF-α, MCP-1, MIP-2, and ICAM-1 mRNA than group C (P < .01). CONCLUSIONS: Aminophylline treatment improved the renal function and indexes of renal inflammation, which suggests that it provided reno-protection against renal I/R injury.
[Mh] Termos MeSH primário: Lesão Renal Aguda/prevenção & controle
Aminofilina/farmacologia
Antagonistas de Receptores Purinérgicos P1/farmacologia
Traumatismo por Reperfusão/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Quimiocina CCL2/metabolismo
Creatinina/metabolismo
Citocinas/metabolismo
Molécula 1 de Adesão Intercelular/metabolismo
Rim/irrigação sanguínea
Testes de Função Renal
Masculino
Camundongos Endogâmicos C57BL
NF-kappa B/metabolismo
Nefrite/prevenção & controle
Infiltração de Neutrófilos/efeitos dos fármacos
Distribuição Aleatória
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ccl2 protein, mouse); 0 (Chemokine CCL2); 0 (Cytokines); 0 (NF-kappa B); 0 (Purinergic P1 Receptor Antagonists); 0 (Tumor Necrosis Factor-alpha); 126547-89-5 (Intercellular Adhesion Molecule-1); 27Y3KJK423 (Aminophylline); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170501
[Lr] Data última revisão:
170501
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE


  6 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28192097
[Au] Autor:Khamseekaew J; Kumfu S; Wongjaikam S; Kerdphoo S; Jaiwongkam T; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
[Ad] Endereço:Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Rese
[Ti] Título:Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
[So] Source:Eur J Pharmacol;799:118-127, 2017 Mar 15.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Although cardiac mitochondrial dysfunction is involved in the pathophysiology of iron-overload cardiomyopathy, the precise mechanisms of iron-induced mitochondrial dysfunction, and the roles of the iron chelator deferiprone and the T-type calcium channel blocker efonidipine on cardiac mitochondrial biogenesis in thalassemic mice are still unknown. ß-thalassemic (HT) mice were fed with a normal diet (ND) or a high iron-diet (FE) for 90 days. Then, the FE-fed mice were treated with deferiprone (75mg/kg/day) or efonidipine (4mg/kg/day) for 30 days. The hearts were used to determine cardiac mitochondrial function, biogenesis, mitochondrial dynamics and protein expressions for oxidative phosphorylation (OXPHOS) and apoptosis. ND-fed HT mice had impaired heart rate variability (HRV), increased mitochondrial dynamic proteins and caspase-3, compared with ND-fed wild-type mice. Iron overload led to increased plasma non-transferrin bound iron, oxidative stress, and the impairments of HRV and left ventricular function, cardiac mitochondrial function and mitochondrial dynamics, and decreased complex IV in thalassemic mice. Our results suggested that deferiprone and efonidipine treatment showed similar benefit in attenuating cardiac iron deposit and oxidative stress, and improved cardiac mitochondrial function, leading to improved left ventricular function, without altering the cardiac mitochondrial biogenesis, and apoptosis proteins in iron-overload thalassemic mice.
[Mh] Termos MeSH primário: Canais de Cálcio Tipo T/metabolismo
Di-Hidropiridinas/farmacologia
Sobrecarga de Ferro/complicações
Miocárdio/patologia
Nitrofenóis/farmacologia
Biogênese de Organelas
Piridonas/farmacologia
Talassemia/tratamento farmacológico
[Mh] Termos MeSH secundário: Aminofilina
Animais
Apoptose/efeitos dos fármacos
Atropina
Pressão Sanguínea/efeitos dos fármacos
Bloqueadores dos Canais de Cálcio/farmacologia
Bloqueadores dos Canais de Cálcio/uso terapêutico
Di-Hidropiridinas/uso terapêutico
Combinação de Medicamentos
Coração/efeitos dos fármacos
Coração/fisiopatologia
Frequência Cardíaca/efeitos dos fármacos
Ferro/sangue
Quelantes de Ferro/farmacologia
Quelantes de Ferro/uso terapêutico
Masculino
Malondialdeído/metabolismo
Camundongos
Mitocôndrias/efeitos dos fármacos
Mitocôndrias/metabolismo
Miocárdio/metabolismo
Nitroglicerina
Nitrofenóis/uso terapêutico
Compostos Organofosforados/farmacologia
Compostos Organofosforados/uso terapêutico
Fosforilação Oxidativa/efeitos dos fármacos
Papaverina
Fenobarbital
Piridonas/uso terapêutico
Transdução de Sinais/efeitos dos fármacos
Talassemia/complicações
Talassemia/metabolismo
Talassemia/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcium Channel Blockers); 0 (Calcium Channels, T-Type); 0 (Dihydropyridines); 0 (Drug Combinations); 0 (Iron Chelating Agents); 0 (Myocardon); 0 (Nitrophenols); 0 (Organophosphorus Compounds); 0 (Pyridones); 27Y3KJK423 (Aminophylline); 2BTY8KH53L (deferiprone); 40ZTP2T37Q (efonidipine); 4Y8F71G49Q (Malondialdehyde); 7C0697DR9I (Atropine); DAA13NKG2Q (Papaverine); E1UOL152H7 (Iron); G59M7S0WS3 (Nitroglycerin); YQE403BP4D (Phenobarbital)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170214
[St] Status:MEDLINE


  7 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28108402
[Au] Autor:Cooney L; McBride A; Lilley A; Sinha I; Johnson TN; Hawcutt DB
[Ad] Endereço:Medical School, University of Liverpool, UK.
[Ti] Título:Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations.
[So] Source:Pulm Pharmacol Ther;43:6-11, 2017 Apr.
[Is] ISSN:1522-9629
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate physiologically based pharmacokinetic modelling (PBPK) software in paediatric asthma patients using intravenous aminophylline. METHODS: Prospective clinical audit of children receiving iv aminophylline (July 2014 to June 2016), and in-silico modelling using Simcyp software. RESULTS: Thirty-eight admissions (25 children) were included. Children with aminophylline levels ≥10 mg/l had equivalent clinical outcomes compared to those <10 mg/L, and adverse effects occurred in 57%. Therapeutic drug monitoring (TDM) data correlated well with PBPK model. PBPK modelling of a 5 mg/kg iv loading dose (≤18yr) shows a mean C of 8.99 mg/L (5th-95th centiles 5.5-13.7 mg/L), with 70.3% of subjects <10 mg/L, 29.4% achieving 10-20 mg/L, and 0.1% > 20 mg/L. For an aminophylline infusion (0-12 y) of 1.0  mg/kg/h, the mean steady state infusion concentration was 16.4 mg/L, (5th-95th centiles 5.3-32 mg/L), with 26.8% having a serum concentration >20 mg/L. For 12-18yr receiving 0.5  mg/kg/h infusion, the mean steady state infusion concentration was 9.37 mg/L (5th-95th centiles 3.4-18 mg/L), with 59.8% having a serum concentration <10 mg/L. CONCLUSION: PBPK software modelling correlates well with clinical data. Current aminophylline iv loading dosage recommendations achieve levels <10 mg/l in 70% of children. Routine TDM may need altering as low risk of toxicity (>20 mg/l).
[Mh] Termos MeSH primário: Aminofilina/farmacocinética
Asma/tratamento farmacológico
Broncodilatadores/farmacocinética
Modelos Biológicos
[Mh] Termos MeSH secundário: Administração Intravenosa
Adolescente
Aminofilina/administração & dosagem
Broncodilatadores/administração & dosagem
Criança
Pré-Escolar
Simulação por Computador
Relação Dose-Resposta a Droga
Monitoramento de Medicamentos/métodos
Feminino
Seres Humanos
Lactente
Masculino
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bronchodilator Agents); 27Y3KJK423 (Aminophylline)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170122
[St] Status:MEDLINE


  8 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27815150
[Au] Autor:Zhou Q; Wang D; Liu Y; Yang X; Lucas R; Fischer B
[Ad] Endereço:Department of High Altitude Geographical and High Altitude Disease, College of High Altitude Military Medicine, Third Military Medical University, and Key Laboratory of High Altitude Medicine, Ministry of Education, Chongqing, China.
[Ti] Título:Solnatide Demonstrates Profound Therapeutic Activity in a Rat Model of Pulmonary Edema Induced by Acute Hypobaric Hypoxia and Exercise.
[So] Source:Chest;151(3):658-667, 2017 Mar.
[Is] ISSN:1931-3543
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The synthetic peptide solnatide is a novel pharmacologic agent that reduces extravascular lung water, blunts reactive oxygen species production, and improves lung function due to its ability to directly activate the epithelial sodium channel. The goal of this study was to investigate the effect of solnatide in pulmonary edema induced by acute hypobaric hypoxia and exercise in rats, which is considered a model for high-altitude pulmonary edema. METHODS: Sprague-Dawley rats were assigned to low-altitude control and eight treatment groups. Animals of all groups were subjected to exhaustive exercise in a hypobaric hypoxic environment simulating an altitude of 4,500 meters, followed by simulated ascent to 6,000 meters. After 48 h at 6,000 meters, rats were given sodium chloride, dexamethasone, aminophylline, p38 mitogen activated protein kinase inhibitor, and NOD-like receptor containing a pyrin domain 3 inhibitor, or one of three different doses of solnatide, once daily for 3 consecutive days. After 3 days, arterial blood gas, BAL fluid, lung water content, and histologic and ultra-microstructure analyses were performed. Tight junction protein occludin was assayed by using immunohistochemistry. RESULTS: Rats treated with solnatide had significantly lower BAL fluid protein and lung water content than high-altitude control rats. Lungs of solnatide-treated rats were intact and showed less hemorrhage and disruption of the alveolar-capillary barrier than those of high-altitude control animals. Occludin expression was significantly higher in solnatide-treated animals, compared with high-altitude control, dexamethasone-, and aminophylline-treated animals. CONCLUSIONS: Solnatide reduced pulmonary edema, increased occludin expression, and improved gas-blood barrier function during acute hypobaric hypoxia and exercise in rats. These results provide a rationale for the clinical application of solnatide to patients with pulmonary edema and exposure to a high-altitude hypoxic environment.
[Mh] Termos MeSH primário: Doença da Altitude/metabolismo
Água Extravascular Pulmonar/efeitos dos fármacos
Hipertensão Pulmonar/metabolismo
Pulmão/efeitos dos fármacos
Peptídeos Cíclicos/farmacologia
Condicionamento Físico Animal
[Mh] Termos MeSH secundário: Doença da Altitude/patologia
Aminofilina/farmacologia
Animais
Gasometria
Líquido da Lavagem Broncoalveolar
Broncodilatadores/farmacologia
Capilares/ultraestrutura
Dexametasona/farmacologia
Glucocorticoides/farmacologia
Hemorragia
Hipertensão Pulmonar/patologia
Imuno-Histoquímica
Pulmão/metabolismo
Pulmão/patologia
Pulmão/ultraestrutura
Microscopia Eletrônica
Ocludina/efeitos dos fármacos
Ocludina/metabolismo
Alvéolos Pulmonares/ultraestrutura
Edema Pulmonar/metabolismo
Edema Pulmonar/patologia
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AP301 peptide); 0 (Bronchodilator Agents); 0 (Glucocorticoids); 0 (Occludin); 0 (Ocln protein, rat); 0 (Peptides, Cyclic); 27Y3KJK423 (Aminophylline); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170529
[Lr] Data última revisão:
170529
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161106
[St] Status:MEDLINE


  9 / 3695 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27574937
[Au] Autor:Muzaffar M; Chai M
[Ad] Endereço:Department of Internal Medicine, Vidant Medical Center, East Carolina University, Greenville, NC.
[Ti] Título:Methotrexate-Induced Acute Necrotizing Leukoencephalopathy: Role of Aminophylline?
[So] Source:Am J Ther;24(1):e104-e105, 2017 Jan/Feb.
[Is] ISSN:1536-3686
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Encefálicas/tratamento farmacológico
Leucoencefalopatias/induzido quimicamente
Linfoma Difuso de Grandes Células B/tratamento farmacológico
Metotrexato/efeitos adversos
[Mh] Termos MeSH secundário: Aminofilina/uso terapêutico
Encéfalo/diagnóstico por imagem
Encéfalo/patologia
Neoplasias Encefálicas/diagnóstico por imagem
Seres Humanos
Leucoencefalopatias/diagnóstico por imagem
Leucoencefalopatias/tratamento farmacológico
Linfoma Difuso de Grandes Células B/diagnóstico por imagem
Imagem por Ressonância Magnética
Masculino
Metotrexato/administração & dosagem
Meia-Idade
Necrose/induzido quimicamente
Necrose/diagnóstico por imagem
Inibidores de Fosfodiesterase/uso terapêutico
Rituximab/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Phosphodiesterase Inhibitors); 27Y3KJK423 (Aminophylline); 4F4X42SYQ6 (Rituximab); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170214
[Lr] Data última revisão:
170214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160831
[St] Status:MEDLINE
[do] DOI:10.1097/MJT.0000000000000480


  10 / 3695 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27142356
[Au] Autor:Aghabiklooei A; Sangsefidi J
[Ad] Endereço:1 Department of Legal Medicine and Toxicology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
[Ti] Título:The effects of intravenous aminophylline on level of consciousness in acute intentional benzodiazepines poisoning in comparison to flumazenil.
[So] Source:Hum Exp Toxicol;36(3):311-316, 2017 Mar.
[Is] ISSN:1477-0903
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: Acute intentional benzodiazepine poisoning is marked by a significant loss of consciousness, aspiration pneumonia, and increased rates of mortality and morbidity, especially in older patients with underlying heart or lung disease. These patients may need flumazenil to reverse the respiratory effects of benzodiazepines. The positive effects of aminophylline on respiration and neonatal apnea improvement have been shown previously. However, its possible effects on increasing the level of consciousness have never been evaluated. METHODS: In a placebo-controlled study, we assessed the effectiveness of aminophylline on increasing the level of consciousness. RESULTS: Time to full awakening was significantly shorter in those who received aminophylline (72 min vs. 881 min, p = 0.001), compared to those who received a placebo. CONCLUSION: When "flumazenil" is contraindicated or unavailable, intravenous aminophylline can be used as a second choice.
[Mh] Termos MeSH primário: Aminofilina/toxicidade
Benzodiazepinas/envenenamento
Estado de Consciência/efeitos dos fármacos
Flumazenil/envenenamento
[Mh] Termos MeSH secundário: Adolescente
Adulto
Aminofilina/administração & dosagem
Seres Humanos
Injeções Intravenosas
Irã (Geográfico)
Meia-Idade
Placebos
Método Simples-Cego
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Placebos); 12794-10-4 (Benzodiazepines); 27Y3KJK423 (Aminophylline); 40P7XK9392 (Flumazenil)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170328
[Lr] Data última revisão:
170328
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160505
[St] Status:MEDLINE
[do] DOI:10.1177/0960327116646619



página 1 de 370 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde